Abstract
A series of twenty-one 7-chloro-4-quinolinylhydrazones derivatives (3a-u) have been synthesized and evaluated for their cytotoxic potential against three cancer cell lines using MTT assay. The compounds 3b, 3e, 3f, 3h, 3j, 3n, 3r and 3u displayed more than 90% of growth inhibition (GI) and they were selected for in vitro anticancer activities evaluation against four human cancer cell lines. These results were expressed as the concentrations that induce 50% inhibition of cell growth (IC50) in μg/mL. Considering that, compounds 3b, 3e, 3h, 3n, 3r and 3u exhibited good cytotoxic activity against at least three cancer cell lines (0.7967- 4.200 μg/mL). In general, we observed that the presence of electronwithdrawing groups in the benzene ring is important for the anticancer activity in this series, such as fluorine (3h), chlorine (3b) amd bromine (3e) groups in meta position and nitro group (3r) in para position. These derivatives could be considered interesting start points to develop a new anticancer drug and confirm the potential of chloroquine derivatives as lead compounds in anticancer drug discovery.
Keywords: Antitumoral activity, cancer, chloroquine, drugs, quinoline, 7-chloro-4-quinolinylhydrazones derivatives, human cancer cell lines, anticancer drug discovery, chloroquine derivatives
Medicinal Chemistry
Title: Synthesis and Antitumoral Evaluation of 7-chloro-4-quinolinylhydrazones Derivatives
Volume: 7 Issue: 6
Author(s): Raquel Carvalho Montenegro, Leticia Veras Lotufo, Manoel Odorico de Moraes, Claudia do O Pessoa, Felipe Augusto Rocha Rodrigues, Marcelle de Lima Ferreira Bispo, Laura Nogueira de Faria Cardoso, Carlos Roland Kaiser and Marcus Vinicius Nora de Souza
Affiliation:
Keywords: Antitumoral activity, cancer, chloroquine, drugs, quinoline, 7-chloro-4-quinolinylhydrazones derivatives, human cancer cell lines, anticancer drug discovery, chloroquine derivatives
Abstract: A series of twenty-one 7-chloro-4-quinolinylhydrazones derivatives (3a-u) have been synthesized and evaluated for their cytotoxic potential against three cancer cell lines using MTT assay. The compounds 3b, 3e, 3f, 3h, 3j, 3n, 3r and 3u displayed more than 90% of growth inhibition (GI) and they were selected for in vitro anticancer activities evaluation against four human cancer cell lines. These results were expressed as the concentrations that induce 50% inhibition of cell growth (IC50) in μg/mL. Considering that, compounds 3b, 3e, 3h, 3n, 3r and 3u exhibited good cytotoxic activity against at least three cancer cell lines (0.7967- 4.200 μg/mL). In general, we observed that the presence of electronwithdrawing groups in the benzene ring is important for the anticancer activity in this series, such as fluorine (3h), chlorine (3b) amd bromine (3e) groups in meta position and nitro group (3r) in para position. These derivatives could be considered interesting start points to develop a new anticancer drug and confirm the potential of chloroquine derivatives as lead compounds in anticancer drug discovery.
Export Options
About this article
Cite this article as:
Carvalho Montenegro Raquel, Veras Lotufo Leticia, Odorico de Moraes Manoel, do O Pessoa Claudia, Augusto Rocha Rodrigues Felipe, de Lima Ferreira Bispo Marcelle, Nogueira de Faria Cardoso Laura, Roland Kaiser Carlos and Vinicius Nora de Souza Marcus, Synthesis and Antitumoral Evaluation of 7-chloro-4-quinolinylhydrazones Derivatives, Medicinal Chemistry 2011; 7 (6) . https://dx.doi.org/10.2174/157340611797928299
DOI https://dx.doi.org/10.2174/157340611797928299 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy
Current Pharmaceutical Design Oncogenic LncRNA CASC9 in Cancer Progression
Current Pharmaceutical Design Gene Expression Studies in Multiple Sclerosis
Current Genomics Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry Endogenous Events Modulating Myogenic Regulation of Cerebrovascular Function
Current Vascular Pharmacology 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry Small Molecule Complementarity As A Source of Novel Pharmaceutical Agents and Combination Therapies
Current Pharmaceutical Design Polysialyltransferase: A New Target in Metastatic Cancer
Current Cancer Drug Targets Optical and Multimodal Peptide-Based Probes for In Vivo Molecular Imaging
Anti-Cancer Agents in Medicinal Chemistry CDC25A: A Rebel Within the CDC25 Phosphatases Family?
Anti-Cancer Agents in Medicinal Chemistry PREFACE
Anti-Cancer Agents in Medicinal Chemistry Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey
Current Pharmaceutical Biotechnology A Progressive Review of V600E-B-RAF-Dependent Melanoma and Drugs Inhibiting It
Mini-Reviews in Medicinal Chemistry NSAIDs and Chemoprevention
Current Cancer Drug Targets Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design Targeting 5-Lipoxygenase for Prevention and Treatment of Cancer
Current Enzyme Inhibition Emerging Adenoviral Vectors for Stable Correction of Genetic Disorders
Current Gene Therapy MET and ALK as Targets for the Treatment of NSCLC
Current Pharmaceutical Design